This is the page description.
As our lives evolve...
....so should the care of how we're treated.
— Welcome to our world of combination products—
We're developing them to make an impact on the health and well being for those that are suffering...
Our core competency is centered around our internal development of complex and novel combination device technologies, to drive down the burden of surgical complications and treatment options that can stress the patient population. Our targeted focuses are centered around working and linking both rare and orphan diseases to the familiar oncology diseases for more diverse efficacious treatment opportunities.
In our heavily intensive research and development nature, we've been working to cross-pollinate technologies that can transform and translate novel device combinations into treatment options in the following areas:
— Project Hyperion —
Eventually to be our flagship product. This device combination is one of a novel development of a "liquid stent"; Targeting alignment with Atrial Myxoma and atrial stenosis leading to coronary arterial disease.
— Project Apollo—
A unique approach to hemoglobin, protein and synthetic cell modification; this combination device is targeting a two pronged approach in the following:
Pantothenate Kinase-Associated Neurodegeneration (PKAN) to Amyotrophic Lateral Sclerosis (ALS)
Paroxysmal Nocturnal Hemoglobinuria (PNH) to Lewy Body Dementia
— Project Icarus—
Pediatric combination device infused with nanotech synthetic cells targeting pediatric patients that suffer from Diffuse Intrinsic Pontine Glioma (DIPG).
More projects to come...
— Project Hercules—
Our initial development and furthest one along in our product development pipeline. Currently in clinical trials. This device is geared toward having your musculoskeletal system regenerate bone, tissue, ligament and muscle in the hip. Targeting arthrodesis & osteopenia to bone marrow disease.